CoChat
Cited by 185

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study

Open access
Thomas, Anish, Vilimas, Rasa, Trindade, Christopher, Erwin-Cohen, Rebecca, Roper, Nitin, Xi, Liqiang, Krishnasamy, Venkatesh, Levy, Elliot, Mammen, Andy, Nichols, Samantha, Chen, Yuanbin, Velcheti, Vamsidhar, Yin, Faye, Szabo, Eva, Pommier, Yves, Steinberg, Seth M., Trepel, Jane B., Raffeld, Mark, Young, Howard A., Khan, Javed, Hewitt, Stephen, Lee, Jung-Min · 2019 · Journal of Thoracic Oncology

Abstract

Purpose: Despite high tumor mutation burden, immune checkpoint blockade has limited efficacy in small cell lung cancer (SCLC). We hypothesized that poly (ADP-ribose) polymerase (PARP) inhibition could render SCLC more susceptible to immune checkpoint blockade. Methods: Single-arm, phase II trial () enrolled relapsed SCLC patients who received durvalumab 1500 mg q 4 weeks and olaparib 300 mg BID. The primary outcome was objective response rate (ORR). Correlative studies included mandatory pre and on-treatment biopsies which were assessed to define SCLC immune-phenotypes: desert (CD8+ T cell prevalence low), excluded (CD8+ T cells in stroma immediately adjacent/within tumor) or inflamed (CD8+ T cells in direct contact with tumor). Results: Twenty patients enrolled. The median age was 64 years and most patients (60%) had platinum-resistant/refractory disease. Of 19 evaluable patients, confirmed partial or complete responses were observed in 2 patients (10.5%), including a patient with EGFR-transformed SCLC. Clinical benefit was observed in four (21.1%; 95% CI: 6.1-45.6%) patients with confirmed responses or prolonged stable disease (8 months+). Most common treatment-related adverse events were anemia (80%), lymphopenia (60%), and leucopenia (50%). Nine of 14 (64%) tumors exhibited an excluded phenotype; 21% and 14% of tumors exhibited inflamed and desert phenotypes, respectively. Tumor responses were observed in all instances when pretreatment tumors showed an inflamed phenotype. Of the five tumors without an inflamed phenotype at baseline, no on-treatment increase in T-cell infiltration or PD-L1 expression on tumor infiltrating immune cells was observed. Conclusions: The combination did not meet the preset bar for efficacy. Pre- and on-treatment biopsies suggest that tumor-immune phenotypes may be relevant for SCLC responses to immune checkpoint blockade combinations. The predictive value of pre-existing CD8+ T-cell infiltrates observed in this study needs to be confirmed in larger cohorts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2019.04.026

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Thomas, A., Vilimas, R., Trindade, C., Erwin-Cohen, R., Roper, N., Xi, L., Krishnasamy, V., Levy, E., Mammen, A., Nichols, S., Chen, Y., Velcheti, V., Yin, F., Szabo, E., Pommier, Y., Steinberg, S. M., Trepel, J. B., Raffeld, M., Young, H. A., Khan, J., Hewitt, S., & Lee, J.-M.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2019-08
Volume
14
Issue
8
Pages
1447-1457
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2944244934
Cited by
185
References
13
FWCI
9.16
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.